Objective: To describe a dementia case clinically diagnosed as Alzheimer disease with a PRNP genotype usually associated with familial fatal insomnia.
A lzheimer disease (AD) is the most common cause of dementia and is a progressive neurodegenerative disorder with an insidious onset. Familial cases with a defined inheritance pattern account for only 5% to 10% of AD cases with an early age at onset and are usually associated with mutations in 3 genes: APP (OMIM #104760), PSEN1 (OMIM #104311), and PSEN2 (OMIM #600759). 1 The fact that clinical phenotypes in dementia are variable, together with the lack of precise and explicit clinical or biochemical antemortem diagnostic markers, leads to the need for a regular differential diagnosis for early onset dementias, 2 such as frontotemporal dementias [associated with mutations in 2 genes: MAPT (OMIM #157140) and PGRN (OMIM #138945)] and prion diseases [associated with mutations in the prion protein gene: PRNP (OMIM #176640)]. 3 In hereditary prion diseases, clinical manifestations are also variable. 4 In both AD and some prion diseases, neurodegeneration may be accompanied by cerebral deposits of amyloid and aggregated tau neurofibrils. 3, 5, 6 Creutzfeldt-Jakob disease (CJD) and Gerstmann-Straussler-Scheinker disease are the prion diseases in which dementia is an important part of the clinical syndrome. The clinical picture of CJD is typically characterized by a rapidly progressive dementia, associated with myoclonus, cerebellar, pyramidal, and extrapyramidal signs. 7 In Gerstmann-Straussler-Scheinker disease, the classic presentation is a cerebellar syndrome with dementia occurring later and a mean duration of disease of 5 years. 8 Familial fatal insomnia (FFI) is an autosomal dominant disorder mainly characterized by neuronal degeneration limited to selected thalamic nuclei, together with progressive insomnia and dysautonomia. FFI is caused by a mutation at codon 178 of the PRNP gene that leads to a D178N substitution in the protein when the amino acid at codon 129 is a methionine on the mutated allele (in cis); the same mutation results in CJD when the amino acid at codon 129 is a valine (in cis). 9 Here, we describe a dementia case with a genotype usually associated with FFI (D178N mutation in ''cis'' with a methionine in codon 129 in the PRNP gene) presenting without insomnia.
METHODS
Informed consent for the participation in this study was obtained from the patient, who was diagnosed as a probable Alzheimer dementia case, according to the standard Diagnostic and Statistical Manual, revision 4 10 criteria and the National Institute of Neurological Disorders and Stroke and the Alzheimer Disease and Related Disorders Association protocol guidelines. 11 Mutation analysis was performed on genomic DNA extracted from saliva, collected using Oragene Kits (DNA Genotek). The coding exons and the respective flanking intronic sequences of PSEN1, PSEN2, PRNP, and PGRN, together with the noncoding exon 0 of the latter; exons 16 and 17 of APP and exons 1, 3, 9, 10, 11, 12, and 13 of MAPT gene were polymerase chain reaction (PCR) amplified using the respective primers (available on request) and Roche FastStart PCR Master Mix polymerase (Roche Diagnostics Corporation, IN). Resulting PCR products were sequenced using the same forward and reverse primers with Applied Biosystems BigDye terminator version 3.1 sequencing chemistry and run on an ABI3730xl genetic analyzer as per manufacturer's instructions. The sequences were analyzed with Sequencher software, version 4.1.4 (Genecodes, VA). In our laboratories, early-onset dementia cases are subject to genetic analysis for the PSEN1, PSEN2, and APP genes. If this analysis is negative, other genes known to underlie early onset dementias are screened (MAPT, PGRN, and PRNP).
RESULTS

Clinical Presentation
The patient, a 51-year-old female born in Macedonia, finished 12 years of education and worked as a nurse. She came into our clinic (Neurological Clinic, Clinical Center, Skopje, Macedonia) at the age of 50 years, reporting a progressive memory loss, depression, mild speech, and language difficulties, and dyspraxia. The patient was aware of her situation and was fearful. On neuropsychologic testing, the patient was time disoriented, her verbal fluency was reduced (2 words for 1 min), and comprehension was altered, but she was able to write. Her ability for new learning was limited and she was not able to recall words that she had learned 20 minutes before, but she was able to partially recognize them. Semantic memory was relatively spared, but episodic memory was much compromised. She could draw a clock. Her SLUMS score was 8/30 (the St Louis University Mental Status from the St Louis University Department of Veterans Affairs is a 30 point screening questionnaire that tests orientation, memory attention and executive function). 12 Four months later, she was disoriented with respect to time and place; and she could not draw a clock. Comprehension was very limited and she could still write, but now with major difficulties. She could copy figures, but was unable to finish the neuropsychologic testing. One year after the first examination, neuropsychologic testing was attempted, but the patient was not testable. The St Louis University Mental Status score at this time was 3 of 30. The electroencephalography revealed slow brain activity, with y and d waves in frontotemporal regions. The computed tomography presented a frontoparietal cortical atrophy and the magnetic resonance imaging showed hyperintense hippocampus, basal ganglia, and temporoparietal cortex signals on T2weighted images. By that time the patient was diagnosed as probable AD.
Three months after, according to information obtained from a caregiver, the patient had global aphasia, could not walk or perform any activities without help (eating, washing, and dressing). She spent all days playing with a doll and could only recognize family members. The patient never had any sleep disturbances.
According to the last information given by a caregiver, the patient is presently bedridden, with major swallowing difficulties, cannot recognize any relatives and is unable to speak.
It is worth noting that the proband's brother presented very alike clinical signs, at a similar age as the proband. By family report, his first symptom was depression followed by complains of memory loss. He died at the age of 52 years, with clinical signs of dementia (progressive memory loss, aphasia, inability to walk, and eating difficulties), approximately 2 years after his first visit to the clinic. He was not formally diagnosed with a neurologic disorder. Additionally, the proband's mother was diagnosed with Pick dementia and she died at the age of 60 years.
It is also worth mentioning that the proband's mother was diagnosed with Pick dementia and she died at the age of 60 years.
Sequence Analysis
The D178N (c.532G>A) mutation was found in the PRNP gene. The patient is homozygous for methionine in the codon 129, thus presenting the D178Ncis-129M genotype, mainly associated with FFI phenotype. No mutations were found in PSEN1, PSEN2, APP, PGRN, or MAPT.
DISCUSSION
The mutation D178N in the PRNP gene is associated with FFI and with CJD. It was first reported in Finnish kindreds 13 and in 1992 a haplotypic relation between codons 129 and 178 in the PRNP gene was established: the D178N mutation associated with the 129M genotype was related to FFI, whereas the same mutation associated with the 129V genotype was linked to familial CJD. 14 However, recent studies have reported some pedigrees segregating both with the FFI and CJD phenotypes. 15, 16 A Japanese family was reported with the D178N-129M genotype and a clinical presentation of cerebellar ataxia without overt insomnia. 17 In addition, sleep disturbances may accompany other PRNP mutations. 18 Thus, the association between the 2 haplotypes and phenotypes is not as linear as first believed.
The median age of onset associated with the D178N mutation (including both codons 129V and M) is 50 years and the median duration of the disease is 11 months. 19 Clinically, patients present memory impairment as the initial symptom and the progression of the disease is similar to the sporadic forms of CJD, with a high frequency of cerebellar, myoclonus, extrapyramidal, and pyramidal signs. 20 However, the distinction between AD and CJD cannot always be made based on clinical and electrophysiologic arguments, as emphasized before by numerous reports. [21] [22] [23] The clinical phenotype of genetic prion diseases (including age of onset and duration of the disease) may be very variable even between members of a family with the same mutation. The present case illustrates two main issues: (1) that genetic prion diseases may not be easy to diagnose and may be erroneously clinically classified as other dementias, including AD and (2) although the current picture is that the mutations are the direct cause requiring no other external factors for the manifestation of the disease, this frequent phenotypic variability may be associated with other genetic and/or environmental factors, apart from the polymorphism in codon 129, still to be identified. 24, 25 In fact, Zarranz et al 24 claim that FFI and CJD may be the extremes of a spectrum rather than two discrete and separate entities. Thus, an early and specific diagnosis of early onset dementia is indispensable to be able to perform a correct clinical assessment, genetic counseling and, eventually, to apply efficient specific treatments. In summary, these data show that, particularly in cases with a rapid progression, screening of PRNP is warranted in suspected AD cases.
